"A common diabetes medication does not help people with peripheral artery disease (PAD) and without diabetes walk farther, according to results from a major U.S. clinical trial published in JAMA. Peripheral artery disease (PAD) is a serious condition that affects blood flow to the legs, making walking painful and difficult. It impacts approximately 12 million adults in the U.S. and is linked to higher risks of heart attack and stroke."
"In the study, investigators tested whether metformin - a widely used, inexpensive drug for type 2 diabetes - could help. Metformin has been shown to improve blood vessel health and reduce oxidative stress, leading scientists to believe it might also benefit PAD patients, even if they don't have diabetes. The study, conducted at four U.S. medical centers, enrolled 202 adults with PAD. Participants were randomly assigned to take either metformin or a placebo for six months."
A randomized, placebo-controlled trial enrolled 202 adults with peripheral artery disease (PAD) at four U.S. medical centers to test whether metformin improves walking performance in people without diabetes. Participants took metformin or placebo for six months and completed six-minute walk tests to measure change in walking distance. Metformin is inexpensive and widely used for type 2 diabetes and has shown vascular and antioxidant effects that suggested possible benefit for PAD. After six months both groups walked shorter distances and the mean difference between metformin and placebo was about one meter, indicating no clinically meaningful improvement.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]